Navigation Links
Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
Date:9/12/2007

September 11, 2007

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr. Edward Jones:

Yesterday's FDA Advisory Committee meeting underscores the many considerations that must be factored in to policymaking related to anemia treatment in patients suffering from chronic kidney disease. The kidney community salutes FDA for working with scientists, practicing nephrologists, and other members of the medical community to achieve a consensus on hemoglobin and dosing levels for erythropoietin-stimulating agents (ESAs) based on different patient populations. The community is unified in its belief that patient quality of care and quality of life must be taken into account as physicians treat anemia in kidney patients. Patients with chronic kidney disease and those on dialysis depend on ESAs to stimulate red blood cell production in their bodies.

Anemia-management drugs have been well demonstrated to improve quality of life for kidney patients and provide significant medical benefits. Unlike patients with cancer, patients with chronic kidney disease are permanently affected by anemia, which in turn affects their ability to engage in day-to- day activities that non-patients take for granted -- caring for their families, holding a job, and going to school. Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were available, blood transfusions were required in most kidney patients. Transfused patients often suffered from heart failure, iron overload, and other chronic problems.

Several studies have demonstrated improvement in the morbidity and mortality of patients with kidney disease and kidney failure by the appropriate management of their anemia. After extensive review of the results of six new studies, a National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) work group updated its Clinical Practice Guidel
'/>"/>

SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... THE WOODLANDS, Texas , Aug. 3, 2015 ... today announced that the pivotal TELESTAR Phase 3 ... benefit of oral telotristat etiprate in treating cancer ... controlled by the current standard of care. Telotristat ... on Nobel Prize-winning technology, and is the company,s ...
(Date:7/31/2015)... 2015  Physicians and payers alone do not ... Patients are better informed and getting increasingly involved ... This shift in power is reshaping the healthcare ... marketing. As part of this evolving ... important to educate, communicate and engage patients throughout ...
(Date:7/31/2015)... July 31, 2015  In today,s ever-changing marketplace, call ... increasingly mobile, increasingly connected, and increasingly impatient with slow ... customer interaction channels and tools is driving call centers ... According to research by benchmarking firm, ... (OTC) segment in a call center study realize the ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
(Date:8/2/2015)... , ... August 03, 2015 , ... ... will be attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) ... , “We are pleased for the opportunity the AHDI conference provides us to ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... 2015 , ... For many “would be” entrepreneurs, starting a new business can prove to ... to start a business.” Neither needs be a major obstacle. , The U.S. has ... a business and be successful. The risks of starting a business can be high but ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/2/2015)... ... 02, 2015 , ... Molecular biologists in New South Wales say a protein ... has just posted an article on the new research. Click here to read ... Ki67 expression in tissue samples from 42 patients with peritoneal mesothelioma and found a ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 Senetek ... engaged in the development of technologies that target the ... quarter and year ended December 31, 2008. Revenue for ... with $26,471,000 reported in 2007. Revenues for the ...
... 31 The following is a statement by Lois ... Senate Majority Leader Smith and Assembly Speaker Silver for ... benefit under one of New York,s most beneficial programs ... program was in danger of losing more than $50 ...
... CITY, Mo., March 31 DST Systems, Inc. (NYSE: ... 50% of Argus Health Systems, Inc. ("Argus"). Argus is now ... in this press release may include forward-looking statements respecting DST ... DST,s views as of today, and actual actions or results ...
... DIEGO, March 31 - Orexigen(R) Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... as President and Chief Executive Officer of the ... M.D., Executive Chairman and Interim President and CEO. ...
... JACKSONVILLE, Fla., March 31 MSC ... products and services to post-discharge and post-injury workers, ... acquired Optimal Translation & Transportation, a national company ... acquisition further fortifies MSC,s position in the market, ...
... 31, 2009 -- Scientists who first established a link ... live in the intestine now are investigating whether the ... Researchers at Washington University School of Medicine in St. ... whether severely malnourished infants living in Malawi and Bangladesh ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: